A Phase 4 interventional study of Farapulse Catheter System and Low-dose Colchicine in Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation and Long-standing Persistent Atrial Fibrillation, sponsored by Vivek Reddy. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Vivek Reddy · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.
Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 4, and was the 19th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
Ayesha Ather · Sites in United States
Ages 18–99
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
Elsan · Sites in France
Ages 18+
By country, each count listing its studies:
Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 14 · Phase 4 4
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 275 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 236 across the 22 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
Vivek Reddy is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
14 studies in Atrial Fibrillation by Vivek Reddy: 1 open now, 3 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 14 studies in Atrial Fibrillation by Vivek Reddy, this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 4, and was the 13th registered.
Vivek Reddy’s Atrial Fibrillation studies by the year they started, since 2009.
3 of the studies testing colchicine in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05890664Phase 3University Hospital, Basel, SwitzerlandColchicine After Electrocardioversion for Atrial Fibrillation | 2027-03 |
| NCT07287345Ayesha AtherColchicine's Effect on Inflammatory Markers | 2026-12-30 |
| NCT06765356Vivek ReddyPragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing colchicine in Atrial Fibrillation, from their registry updates:
Among Vivek Reddy’s 14 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this pragmatic study is to evaluate the safety, performance and effectiveness of the FARAPULSE catheter system (FARAWAVE catheter used in combination with the FARASTAR generator), to treat patients with atrial fibrillation during clinically-indicated ablation procedures
By virtue of its efficiency, safety profile, and potential for improved efficacy, there is tremendous excitement about the role of pulsed field ablation (PFA) to treat atrial fibrillation. Indeed, multiple FDA IDE clinical trials on PFA have been, or are being, conducted to treat AF. However, most FDA pivotal trials studying PFA enroll very selected populations and have highly focused inclusion/exclusion criteria and, typically only paroxysmal or persistent AF patients with limited upper age criteria are included, failure of Class I/III AADs is often required, and other disease states that may particularly benefit from PFA (e.g., PFA might be particularly effective in treating HCM pts with their thickened atrial tissue).
In observational European studies of the FARAPULSE catheter system, the technology has proved quite safe and effective in treating most patients with AF. It is a highly efficient ablation system, and can be employed with only deep sedation, and without the need for endotracheal intubation. In addition to the FARAWAVE catheter performing PV isolation and ablation of the posterior left atrium, in the MANIFEST-PF post-approval study of EU experience, the FARAWAVE catheter has also been shown able to create other relevant ablation lesions such as cavo-tricuspid isthmus ablation for typical atrial flutter, or a mitral isthmus line for mitral isthmus flutter.
The FARAWAVE multielectrode pentaspline PFA catheter is the study device. It can be deployed in a basket or flower configuration: 1) Both configurations can be used to isolate PVs, 2) The flower configuration can be used to ablate the posterior wall, and 3) Flower configuration for creation of CTI or Mitral Isthmus Lines.
The ablation procedure will typically follow the below sequence:
Additional ablation lesion sets are per investigators' discretion:
This study is a prospective, multi-center, non-randomized, investigator-initiated IDE clinical study to determine the safety and efficacy of the recently FDA-approved FARAPULSE system to treat the "usual" patients presenting in clinical practice for catheter ablation of AF. (An IDE is required because the approval for the FARAPULSE system: i) only includes paroxysmal AF patients, and ii) doesn't include the technology's use for linear lesions such as the cavo-tricuspid isthmus line. Participants will be followed for 12-months post-procedure.
There is an optional randomized sub-study looking at the utility of peri-procedural low-dose colchicine in attenuating PFA-related pericardial inflammation and its negative effects (symptoms and atrial arrhythmias). Participants will start low-dose colchicine 5 days prior to PFA procedure and continue up to 3 weeks post-PFA treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with atrial fibrillation with or without concomitant atrial flutter by at some point in the past, and by any criteria (ECG or clear symptoms within the past year)
Planned for a clinically-indicated catheter ablation procedure for managing paroxysmal or persistent atrial fibrillation in accordance with the following recommendations in the ACC/AHA/ACCP/HRS guidelines
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will receive treatment using the Farapulse catheter system (Farawave catheter used in combination with the Farastar generator).
Device: Farapulse Catheter System · Drug: Low-dose Colchicine
The FARAWAVE PFA Catheter is a sterile, single use, over-the-wire, non-deflectable device that is used with the FARASTAR Catheter Connection Cable and FARASTAR Generator to enable delivery of Pulsed Field Ablation energy for irreversible electroporation. The FARAWAVE PFA Catheter has five (5) variably deployable splines. The five splines are undeployed during insertion and removal and during use can deploy continuously from an undeployed state through a partially deployed ("basket-shaped") configuration to a fully deployed ("flower-shaped") configuration with five petals.
For participants in the colchicine sub-study, 0.3 mg BID Colchicine. Colchicine will be prescribed to the patient starting 5 days prior to ablation. Patient will continue the colchicine for 3 weeks post-ablation.
Number of Acute Procedural Success
Acute Procedural Success is defined as confirmation of entrance block in all targeted PVs, and acute block of all linear lesions that are attempted (eg, CTI or mitral isthmus line). (The use of a non-study catheter for PVI will be considered an effectiveness failure; however, use of a non-study catheter for ablation unrelated to PVI will be noted, but not considered a treatment failure)
Time frame: at the end of the procedure (approximately 60 minutes)
Number of Chronic Single-Procedure Success
Chronic Single-Procedure Success is defined as freedom from all of the following: * Any Detectable AF, AFL or AT; * Any re-ablation for AF, AFL or AT; * Any cardioversion for AF, AFL or AT; * Any use of a non-Failed Class I/III AAD or Amiodarone Where "Detectable AF, AFL or AT" refers to either of the following as recorded by the ICM: * Symptomatic (patient-initiated) recording containing ≥ 30 seconds of continuous AF or AT/AFL * Automatically-detected AF or AT/AFL episodes measured at ≥1 hour in duration (asymptomatic)
Time frame: up to 12 months post procedure
Number of Participant to Achieve Linear Lesion Bidirectional Block
Ability to achieve linear lesion bidirectional block using the Farawave catheter alone; for this endpoint, all linear lesions (CTI and Mitral Isthmus) will be aggregated. This will be ascertained acutely after either a 20 min waiting period or despite pharmacologic stress (eg., IV adenosine or IV isoproterenol).
Time frame: at the end of the procedure (approximately 60 minutes)
Incidence of Primary Adverse Events (PAEs)
Incidence of Primary Adverse Events (PAEs) (within 7 days of the initial procedure). PAEs include the following AEs: * Atrio-Esophageal Fistula * Phrenic Nerve Paralysis * Cardiac Tamponade/perforation * Pulmonary Vein Stenosis * Death * Stroke/CVA * Major Vascular Access * Complication/Bleeding * Thromboembolism * Myocardial Infarction TIA * Device or procedure related death * pulmonary vein stenosis and atrio-esophageal fistula that occur greater than one week (7 days) post-procedure are also considered and analyzed as primary AEs.
Time frame: within 7 days of procedure
Number of patients who developed pericarditis
Number of patients who developed clinical pericarditis within 2 weeks following ablation. This will be ascertained by comprehensive chart review plus at the routine post-ablation follow-up phone visit at 7 days
Time frame: within 2 weeks from procedure, and at 7 days follow-up visit
Incidence of Serious Adverse Device Effects (SADEs)
Incidence of Serious Adverse Device Effects (SADEs)
Time frame: end of study at 12 months
Incidence of Gastrointestinal symptoms
Incidence of Gastrointestinal symptoms (necessitating cessation of colchicine therapy) for participants in the substudy
Time frame: end of study at 12 months
Freedom from detectable AF, AFL or AT off AADs
Freedom from detectable AF, AFL or AT off AADs, defining detectable AF, AFL or AT as Freedom from detectable AF, AFL or AT
Time frame: end of study 12 months
Number of patients who achieve CT isthmus block
Number of patients achieving CT isthmus block using the Farawave catheter alone will be recorded.
Time frame: end of study 12 months
Freedom from persistent AF at 12 months off AADs
Freedom from persistent AF at 12 months off AADs
Time frame: end of study 12 months
Freedom from symptomatic AT/AF/AFL recurrence
Freedom from symptomatic AT/AF/AFL recurrence
Time frame: end of study 12 months
Change in Blood interleukin-6
Inflammation is common among those with type 2 diabetes. Inflammatory markers (chemicals in the body that lead to inflammation), such as interleukin-6 (Il-6) have been found to be increased in those with type 2 diabetes For participants in substudy.
Time frame: 5 days pre-PFA and 48-72 hours post-PFA
Change in C-reactive protein (CRP)
C-reactive protein (CRP) is produced by the liver. The CRP test is a general test to check for inflammation in the body. It is not a specific test. This means it can reveal that inflammation somewhere in the body, but it cannot pinpoint the exact location or reason. The CRP test is often done with the ESR (erythrocyte or sedimentation rate) test which also looks for inflammation. For participants in substudy.
Time frame: 5 days pre-PFA and 48-72 hours post-PFA
Changes in Tumor Necrosis Factor (TNF)-α
Many people take medicines to reduce the immune system's abnormal response. These are called immunosuppressive medicines. Targeted drugs such as tumor necrosis factor (TNF) blockers can be used for some diseases. For participants in substudy.
Time frame: 5 days pre-PFA and 48-72 hours post-PFA
Changes in Erythrocyte Sedimentation Rate (ESR)
Erythrocyte sedimentation rate (ESR) is also commonly called a sed rate. It is a test that indirectly measures the level of certain proteins in the blood. This measurement correlates with the amount of inflammation in the body. For participants in substudy.
Time frame: 5 days pre-PFA and 48-72 hours post-PFA
Brain natriuretic peptide (BNP) levels
Brain natriuretic peptide (BNP) test is a blood test that measures levels of a protein called BNP that is made by the heart and blood vessels. BNP levels go up when the heart cannot pump the way it should. A result greater than 100 pg/mL is abnormal. The higher the number, the more likely heart failure is present and the more severe it is. For participants in substudy.
Time frame: 5 days pre-PFA and 48-72 hours post-PFA
Change in durability of lesion sets in any patient that undergoes a second procedure
Change in Durability of lesion sets in any patient that undergoes a second procedure (block across attempted lines, absence of electrograms in targeted substrate). Observe if the block(s) achieved at the targeted sites from the index procedure have persisted
Time frame: baseline (index procedure) and end of study 12 months
Plan to share: No
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 23 months is below that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colchicine
Vivek Reddy